Piramal Pharma Ltd
NSE:PPLPHARMA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
115.5
293.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Piramal Pharma Ltd
Total Receivables
Piramal Pharma Ltd
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Piramal Pharma Ltd
NSE:PPLPHARMA
|
Total Receivables
₹24.6B
|
CAGR 3-Years
43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Total Receivables
₹80.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Total Receivables
₹55.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Total Receivables
₹129.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Total Receivables
₹17.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Total Receivables
₹9.4B
|
CAGR 3-Years
18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Piramal Pharma Ltd
Glance View
Piramal Pharma Ltd. engages in development and manufacturing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 0 full-time employees. The company went IPO on 2022-10-19. The firm has approximately 15 global facilities and a global distribution network in over 100 countries. The firm's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC's complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anesthetics, injectable anti-infectives, and other therapies.
See Also
What is Piramal Pharma Ltd's Total Receivables?
Total Receivables
24.6B
INR
Based on the financial report for Mar 31, 2024, Piramal Pharma Ltd's Total Receivables amounts to 24.6B INR.
What is Piramal Pharma Ltd's Total Receivables growth rate?
Total Receivables CAGR 3Y
43%
Over the last year, the Total Receivables growth was 15%. The average annual Total Receivables growth rates for Piramal Pharma Ltd have been 43% over the past three years .
You don't have any saved screeners yet
